Akira Ainai

Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses.

PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.

Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.

The first autopsy case of pandemic influenza (A/H1N1pdm) virus infection in Japan: detection of a high copy number of the virus in type II alveolar epithelial cells by pathological and virological examination.

Characterization of quasispecies of pandemic 2009 influenza A virus (A/H1N1/2009) by de novo sequencing using a next-generation DNA sequencer.

Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus.

Cross-protective immunity against influenza virus infections induced by intranasal vaccination together with a TLR3-mucosal adjuvant.

A novel function of the N-terminal domain of PA in assembly of influenza A virus RNA polymerase.

Outer membrane vesicles of Porphyromonas gingivalis elicit a mucosal immune response.

Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine.

Mucosal IgA responses in influenza virus infections; thoughts for vaccine design.

The host protease TMPRSS2 plays a major role in in vivo replication of emerging H7N9 and seasonal influenza viruses.

Combatting infectious diseases; nanotechnology as a platform for rational vaccine design.

Cytokine profile of bronchoalveolar lavage fluid from a mouse model of bronchial asthma during seasonal H1N1 infection.

Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus.

Host Adaptation and the Alteration of Viral Properties of the First Influenza A/H1N1pdm09 Virus Isolated in Japan.

Protective antibody responses against A(H1N1)pdm09 primed by infection and recalled by intranasal vaccination.

The effect of mucoadhesive excipient on the nasal retention time of and the antibody responses induced by an intranasal influenza vaccine.

Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?

Impacts of allergic airway inflammation on lung pathology in a mouse model of influenza A virus infection.

Intranasal Administration of Whole Inactivated Influenza Virus Vaccine as a Promising Influenza Vaccine Candidate.

Functional and structural characteristics of secretory IgA antibodies elicited by mucosal vaccines against influenza virus.

Pulmonary inflammation and cytokine dynamics of bronchoalveolar lavage fluid from a mouse model of bronchial asthma during A(H1N1)pdm09 influenza infection.

The road to a more effective influenza vaccine: Up to date studies and future prospects.

cGAMP Promotes Germinal Center Formation and Production of IgA in Nasal-Associated Lymphoid Tissue.

Neutralizing Antibodies Induced by Gene-Based Hydrodynamic Injection Have a Therapeutic Effect in Lethal Influenza Infection.

IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration.

Application of HTLV-1 tax transgenic mice for therapeutic intervention.

Tuberculous pneumonia-induced severe ARDS complicated with DIC in a female child: a case of successful treatment.

Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics.

IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody.